Wed, June 17, 2026
AUS Edition NZ Edition UK Edition
CA Edition USA Edition IND Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. MXCT
Healthcare
Facebook Twitter Linkedin

MaxCyte Inc (NASDAQ:MXCT)

1.14 USD

-0.020 1.724%
Last Updated at: 2026-06-16T20:01:00Z

MaxCyte Inc

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

9713 Key West Avenue, Rockville, MD, United States, 20850

301 944 1700

https://www.maxcyte.com

Employees: 143

Key Executives

Sr. No. Name Title Year Born
1. Mr. Douglas Arthur Doerfler Founder, Pres, CEO & Exec. Director 1956
2. Mr. Ronald Evan Holtz CPA, Ph.D. Chief Financial Officer 1958
3. Dr. J. Stark Thompson Ph.D. Consultant 1942
4. Dr. Cenk Sumen Chief Scientific Officer 1973
5. Mr. Sean Menarguez Director of Investor Relations NA
6. Mr. Maher Masoud Exec. VP, Gen. Counsel & Sec. 1975
7. Mr. Thomas Michael Ross Exec. VP of Global Sales 1961
8. Dr. James Brady Ph.D. Sr. VP of Technical Applications & Customer Support NA
9. Dr. Sarah Haecker Meeks Ph.D. Sr. VP of Bus. Devel. NA
10. Mr. James Lovgren Sr. VP of Global Marketing NA

Peers

Sector: Healthcare

Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
ABT

Abbott Laboratories

 +1.950 2.199% 89.355 25.970 17.241 3.570 3.200 3.805 16.753
SYK

Stryker Corporation

 +2.640 0.857% 309.24 44.070 24.938 5.509 6.118 6.050 25.731
MDT

Medtronic PLC

 +0.940 1.169% 81.3 26.600 15.873 3.354 2.083 3.897 14.117
BSX

Boston Scientific Corp

 +0.160 0.342% 47.25 31.490 17.241 4.407 3.650 4.878 19.194

Income Statement

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Income Before Tax -23.571M -19.082M -11.816M -12.895M -8.869M
Minority Interest - - - - -
Net Income -19.781M -20.127M -12.642M -13.576M -8.869M
Selling General Administrative 25.829M 18.676M 8.386M 6.088M 5.284M
Gross Profit 39.163M 30.247M 23.402M 19.122M 14.827M
Reconciled Depreciation 2.698M 1.424M 1.048M 0.614M 0.344M
Ebit -27.361M -18.189M -11.057M -12.42M -8.255M
Ebitda -20.746M -16.614M -9.943M -11.6M -7.911M
Depreciation And Amortization 6.615M 1.575M 1.114M 0.82M 0.344M
Operating Income -27.361M -18.189M -11.057M -12.42M -8.425M
Other Operating Expenses 71.622M 52.083M 37.226M 34.041M 25.092M
Interest Expense 0.127M 1.044M 0.826M 0.681M 0.615M
Tax Provision 0M 0M - - -
Interest Income 3.917M 0.151M 0.066M 0.206M 0.17M
Net Interest Income 3.79M -0.894M -0.76M -0.475M -0.444M
Income Tax Expense -3.79M 1.044M 0.826M 0.681M 0.17M
Total Revenue 44.262M 33.894M 26.169M 21.621M 16.667M
Total Operating Expenses 66.524M 48.435M 34.459M 31.542M 23.252M
Cost Of Revenue 5.098M 3.647M 2.767M 2.499M 1.84M
Total Other Income Expense Net 3.79M -0.894M -0.76M -0.475M -0.444M
Net Income From Continuing Ops -23.571M -19.082M -11.816M -12.895M -8.869M
Net Income Applicable To Common Shares -23.571M -19.082M -11.816M -12.895M -8.869M

Balance Sheet

(Currency in USD)
Breakdown 31-12-2023 31-12-2022 31-12-2021 31-12-2020 31-12-2019
Total Assets 268.274M 286.653M 284.12M 51.78M 29.985M
Intangible Assets - - - - -
Other Current Assets 3.899M 2.779M 3.307M 1.003M 0.797M
Total Liab 36.107M 32.686M 21.223M 18.555M 16.384M
Total Stockholder Equity 232.167M 253.967M 262.897M 33.225M 13.602M
Other Current Liab 11.269M 8.025M 6.524M 5.209M 3.552M
Common Stock 1.04M 1.024M 1.012M 0.774M 0.574M
Capital Stock 1.04M 1.024M 1.012M 0.774M 0.574M
Retained Earnings -175.798M -137.875M -114.305M -95.222M -83.406M
Good Will - - - - -
Other Assets - 0.809M 0.317M 0.034M -
Cash 46.506M 11.065M 47.782M 18.755M 15.211M
Cash And Equivalents - - - - -
Total Current Liabilities 17.855M 15.427M 15.618M 11.614M 9.343M
Current Deferred Revenue 5.069M 6.713M 6.747M 4.843M 3.193M
Net Debt -27.763M 5.03M -42.1M -11.789M -8M
Short Term Debt 0.774M 0.157M 0.527M 0.673M 0.509M
Short Long Term Debt - - - - -
Short Long Term Debt Total 18.743M 16.095M 5.682M 6.966M 7.211M
Other Stockholder Equity 406.925M 390.819M 376.19M 127.674M 96.434M
Property Plant Equipment - 23.725M 13.371M 6.493M 5.533M
Total Current Assets 190.194M 252.266M 270.433M 45.253M 24.452M
Long Term Investments 42.938M - - - -
Short Term Investments 121.782M 216.275M 207.261M 16.008M 1.498M
Net Receivables 5.778M 13.567M 6.877M 5.172M 3.245M
Long Term Debt - - - 4.917M 4.895M
Inventory 12.229M 8.581M 5.205M 4.316M 3.702M
Accounts Payable 0.743M 0.532M 1.82M 0.89M 2.089M
Accumulated Other Comprehensive Income - - - - -
Non Currrent Assets Other 0.388M 0.809M 0.317M 0.034M -
Non Current Assets Total 78.08M 34.387M 13.687M 6.527M 5.533M
Capital Lease Obligations 18.743M 16.095M 5.682M 2.049M 2.316M
Long Term Debt Total - - - - -

Cash Flow

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Investments -6.346M -191.184M -14.506M 1.726M -3.123M
Total Cashflows From Investing Activities -24.823M -195.013M -16.578M 0.455M -3.833M
Total Cash From Financing Activities 2.889M 234.72M 28.905M 12.311M 0.227M
Net Income -23.571M -19.082M -11.816M -12.895M -8.869M
Change In Cash -36.718M 29.027M 3.544M 3.963M -14.094M
Begin Period Cash Flow 47.782M 18.755M 15.211M 11.248M 25.342M
End Period Cash Flow 11.065M 47.782M 18.755M 15.211M 11.248M
Total Cash From Operating Activities -14.783M -10.68M -8.782M -8.803M -10.487M
Depreciation 2.698M 1.424M 1.048M 0.614M 0.344M
Other Cashflows From Investing Activities - 0.005M - - -
Dividends Paid - - - - -
Change To Inventory -3.493M -1.406M -0.891M -1.89M -1.29M
Sale Purchase Of Stock 2.889M 239.709M - - -
Other Cashflows From Financing Activities -2885.612M 3.631M 1.841M 5.086M 0.284M
Capital Expenditures 18.477M 3.834M 2.072M 1.271M 0.71M
Change In Working Capital -3.211M -1.645M -0.858M 1.613M -3.458M
Other Non Cash Items -2.452M 0.057M 0.102M 0.077M 0.075M
Free Cash Flow -33.26M -14.514M -10.854M -10.074M -11.197M

Funds

Sr. No. Name Purchased On Shares
1. MFS New Discovery I 2 years ago 1667412
2. Swedbank Robur USA A 2 years ago 1600000
3. Vanguard Institutional Extnd Mkt Idx Tr 2 years ago 1554953
4. ES R&M UK Listed Smaller Coms B Acc 2 years ago 1500000
5. Fidelity VIP Growth Initial 2 years ago 1227700
6. Fidelity Advisor Equity Growth I 2 years ago 1127055
7. Morgan Stanley Inception 2 years ago 1053070
8. Morgan Stanley Inst Inception I 2 years ago 1040149
9. MI Chelverton UK Equity Growth B Acc 2 years ago 900365
10. Columbia Small Cap Growth 2 years ago 898111
11. Columbia Small Cap Growth Inst 2 years ago 898111
12. Fidelity Small Cap Index 2 years ago 895537
13. Amati AIM VCT Ord 2 years ago 847256
14. Strategic Advisers Small-Mid Cap 2 years ago 806151
15. iShares Russell 2000 Value ETF 2 years ago 746498
16. iShares Biotechnology ETF 2 years ago 684546
17. Vanguard Total Stock Mkt Idx Inv 2 years ago 2822768
18. Unicorn AIM VCT Ord 2 years ago 2485500
19. iShares Russell 2000 ETF 2 years ago 2033052
20. IFSL Marlborough UK Micro Cap Gr A Acc 2 years ago 1750000

Institutions

Sr. No. Name Purchased On Shares
1. BlackRock Inc 2 years ago 7341386
2. Cadian Capital Management LP 2 years ago 6560484
3. Millennium Management LLC 2 years ago 6171046
4. Vanguard Group Inc 2 years ago 5347112
5. Vitruvian Partners 2 years ago 5043356
6. Morgan Stanley - Brokerage Accounts 2 years ago 3481010
7. FMR Inc 2 years ago 2833715
8. Massachusetts Financial Services Company 2 years ago 2525124
9. Mudita Advisors LLP 2 years ago 2275381
10. Geode Capital Management, LLC 2 years ago 2096497
11. State Street Corporation 2 years ago 1943997
12. River & Mercantile Asset Management LLP 2 years ago 1888642
13. Portolan Capital Management, LLC 2 years ago 1721777
14. Ameriprise Financial Inc 2 years ago 1448907
15. Chevy Chase Trust Holdings, Inc. 2 years ago 1296397
16. ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 2 years ago 1258200
17. Dimensional Fund Advisors, Inc. 2 years ago 889202
18. Northern Trust Corp 2 years ago 795086
19. Silvercrest Asset Management Group LLC 2 years ago 699089
20. Blue Water Life Science Advisors, LLC 2 years ago 603937
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Sponsored Articles

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App